285 related articles for article (PubMed ID: 16923411)
1. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
[TBL] [Abstract][Full Text] [Related]
2. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
Gonin JM; Nguyen H; Gonin R; Sarna A; Michels A; Masri-Imad F; Bommareddy G; Chassaing C; Wainer I; Loya A; Cary D; Barker LF; Assefi A; Greenspan R; Mahoney D; Wilcox CS
J Nephrol; 2003; 16(4):522-34. PubMed ID: 14696754
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design for the CARDIOVIT Study (Cardiovit, Atherosclerotic vascular disease and hypeRhomocysteinemia: an epiDemiological study in Indians, additionally evaluating the effect of Oral VITamin supplementation).
Shenoy KT; Lena KB; Sali N; Syam S; Shenoy ST; Rajadhyaksha VD; Pai GP; Shaikh AA;
Curr Med Res Opin; 2006 Apr; 22(4):641-8. PubMed ID: 16684424
[TBL] [Abstract][Full Text] [Related]
4. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.
Heinz J; Kropf S; Domröse U; Westphal S; Borucki K; Luley C; Neumann KH; Dierkes J
Circulation; 2010 Mar; 121(12):1432-8. PubMed ID: 20231532
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
Heinz J; Kropf S; Luley C; Dierkes J
Am J Kidney Dis; 2009 Sep; 54(3):478-89. PubMed ID: 19359080
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
7. B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial.
Scott TM; Rogers G; Weiner DE; Livingston K; Selhub J; Jacques PF; Rosenberg IH; Troen AM
J Prev Alzheimers Dis; 2017; 4(3):174-182. PubMed ID: 29182708
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
Bleie Ø; Semb AG; Grundt H; Nordrehaug JE; Vollset SE; Ueland PM; Nilsen DW; Bakken AM; Refsum H; Nygård OK
J Intern Med; 2007 Aug; 262(2):244-53. PubMed ID: 17645592
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.
Mann JF; Sheridan P; McQueen MJ; Held C; Arnold JM; Fodor G; Yusuf S; Lonn EM;
Nephrol Dial Transplant; 2008 Feb; 23(2):645-53. PubMed ID: 18003666
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
Zoungas S; McGrath BP; Branley P; Kerr PG; Muske C; Wolfe R; Atkins RC; Nicholls K; Fraenkel M; Hutchison BG; Walker R; McNeil JJ
J Am Coll Cardiol; 2006 Mar; 47(6):1108-16. PubMed ID: 16545638
[TBL] [Abstract][Full Text] [Related]
11. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
Dad T; Tighiouart H; Joseph A; Bostom A; Carpenter M; Hunsicker L; Kusek JW; Pfeffer M; Levey AS; Weiner DE
Am J Kidney Dis; 2016 Aug; 68(2):277-286. PubMed ID: 26947217
[TBL] [Abstract][Full Text] [Related]
12. Baseline characteristics of participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
Bostom AG; Carpenter MA; Hunsicker L; Jacques PF; Kusek JW; Levey AS; McKenney JL; Mercier RY; Pfeffer MA; Selhub J;
Am J Kidney Dis; 2009 Jan; 53(1):121-8. PubMed ID: 19022547
[TBL] [Abstract][Full Text] [Related]
13. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
14. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
Jamison RL; Hartigan P; Kaufman JS; Goldfarb DS; Warren SR; Guarino PD; Gaziano JM;
JAMA; 2007 Sep; 298(10):1163-70. PubMed ID: 17848650
[TBL] [Abstract][Full Text] [Related]
15. Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results.
Zoungas S; Branley P; Kerr PG; Ristevski S; Muske C; Demos L; Atkins RC; Becker G; Fraenkel M; Hutchison BG; Walker R; McNeil JJ; McGrath BP
Nephrology (Carlton); 2004 Jun; 9(3):130-41. PubMed ID: 15189174
[TBL] [Abstract][Full Text] [Related]
16. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.
Suliman ME; Lindholm B; Bárány P; Qureshi AR; Stenvinkel P
Semin Dial; 2007; 20(6):523-9. PubMed ID: 17991198
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine, B-vitamins and CVD.
McNulty H; Pentieva K; Hoey L; Ward M
Proc Nutr Soc; 2008 May; 67(2):232-7. PubMed ID: 18412997
[TBL] [Abstract][Full Text] [Related]
19. Homocysteine or renal impairment: which is the real cardiovascular risk factor?
Potter K; Hankey GJ; Green DJ; Eikelboom JW; Arnolda LF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1158-64. PubMed ID: 18356552
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients.
Beavers KM; Beavers DP; Bowden RG; Wilson RL; Gentile M
Nephrology (Carlton); 2008 Jun; 13(4):284-8. PubMed ID: 18331436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
